ecancermedicalscience

Conference Report

Phase 0 workshop at the 20th EORTC-NCI-AACR symposium, Geneva

12 Nov 2008
S Camporesi

Are phase 0 clinical trials really necessary?

This question was posed by James Doroshow (National Cancer Institute, Bethesda, USA) at the 20th EORT-NCI-AARC Symposium on Molecular Targets and Cancer Therapeutics (Geneva, 21–24 October 2008). Together with E Leo (Beerse, Belgium), James Doroshow-since 2004 Director of the Division of Cancer Treatment and Diagnosis at NCI-was co-chairing the workshop on phase 0 clinical trials. In his introduction to the speakers, Doroshow raised six open questions, namely whether phase 0 trials are useful, ethically acceptable, feasible, whether they speed up the drug development process and save money, and whether there is room for improvement.

Related Articles

Mauro Daniel Spina Donadio, Dirce Maria Carraro, Giovana Tardin Torrezan, Celso Abdon Lopes de Mello
Tiago Cordeiro Felismino, Felipe Marcio Araujo Oliveira, Camilla Albina Zanco Fogassa, Silvia Nardozza Santerini, Victor Hugo Fonseca de Jesus, Rachel Simões Pimenta Riechelmann, Felipe José Fernandez Coimbra, Celso Abdon Lopes Mello
Isabel Saffie Vega, Jorge Sapunar Zenteno, Felipe Buscaglia Fernandez, Felipe Reyes Cosmelli, Rodrigo Lagos Chavez, Badir Chahuán Manzur
Lakhan Kashyap, Vijay Patil, Vanita Noronha, Amit Joshi, Nandini Menon, Kunal Jobanputra, Saswata Saha, Pankaj Chaturvedi, Shripad D Banavali, Kumar Prabhash
Hardenson Rodríguez González, Sergio Andrade Mejía, Javier Orlando Contreras Ortiz, Adriana Patricia Osorno Gutiérrez, Jorge Eliécer Botero López, Javier Enrique Fox Quintana